With malaria being one of the most significant causes of morbidity and mortality worldwide, prompt and effective treatment is essential to reduce the malaria burden. As there are several treatment ...

Full inhibition of liver stage parasite development will lead to true causal prophylaxis. Failure to develop a drug with true causal prophylactic activity against malaria is mostly related to the ...

Tafenoquine is currently approved in the US for malaria prophylaxis under the name Arakoda. The Walter Reed Army Institute of Research discovered the therapy, whose safety profile has been ...

Resistance to antimalarial drugs is a growing concern with research indicating that resistance to first-line treatments has ...

Degrees Pharmaceuticals (SXTP) announced that the United States Food and Drug Administration does not object to the company’s plan to import ...

Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company today announced ...

The import of KODATEF ensures continued availability of tafenoquine for malaria prophylaxis amidst growing demand for ARAKODA in the U.S. ARAKODA is taken as a loading dose of 2 x 100 mg tablets ...

An international research team led by Queen’s University Belfast is developing a long-acting preventative treatment for ...

He said that children from the age of three months to 59 months in more than 10, 000 communities in the 17 local government ...

Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently ...

A systematic search for economic evaluations (i.e., cost–effectiveness, cost–utility and cost–benefit analyses) was conducted comparing ACTs to other malaria therapies and prevention ...